These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24861797)

  • 1. Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
    Holy EW; Beer JH
    Semin Hematol; 2014 Apr; 51(2):131-8. PubMed ID: 24861797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
    Fontana P; Goldhaber SZ; Bounameaux H
    Eur Heart J; 2014 Jul; 35(28):1836-43. PubMed ID: 24510637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
    Prandoni P; Temraz S; Taher A
    Semin Hematol; 2014 Apr; 51(2):121-30. PubMed ID: 24861796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
    van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV
    J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
    Dobesh PP; Fanikos J
    Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
    Farley TM; Lewis D; Macaulay TE
    Orthopedics; 2009 Jan; 32(1):35. PubMed ID: 19226034
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
    Yeh CH; Gross PL; Weitz JI
    Blood; 2014 Aug; 124(7):1020-8. PubMed ID: 24923298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
    Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are new oral anticoagulant dosing recommendations optimal for all patients?
    Powell JR
    JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
    [No Abstract]   [Full Text] [Related]  

  • 15. [Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
    Einecke D
    MMW Fortschr Med; 2013 Apr; 155(6):26-7. PubMed ID: 23700693
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
    Morris TA
    Clin Chest Med; 2010 Dec; 31(4):707-18. PubMed ID: 21047577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct acting oral anticoagulants in venous thromboembolism].
    Walti C; Bächli E
    Praxis (Bern 1994); 2015 Jul; 104(15):771-80. PubMed ID: 26204334
    [No Abstract]   [Full Text] [Related]  

  • 19. New oral therapies for the prevention and treatment of venous thromboembolism.
    Hellwig T; Gulseth M
    Am J Health Syst Pharm; 2013 Jan; 70(2):113-25. PubMed ID: 23292264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.